Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pot and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pot and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)

Saved in:
Bibliographic Details
Published in:Vaccine Vol. 29; no. 46; p. 8309
Main Authors: Garcia, F, Lopez, Bernaldo de Quiros JC, Gomez, CE, Perdiguero, B, Najera, JL, Jimenez, V, Garcia-Arriaza, J, Guardo, AC, Perez, I, Diaz-Brito, V
Format: Journal Article
Language:English
Published: 26-10-2011
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0264-410X
DOI:10.1016/j.vaccine.2011.08.098